Pharmaceutical research and development (R&D) in cardiovascular diseases is hibernating. This research collaboration between the LSE and UCL will tackle high failure rates in R&D in cardiovascular disease. It will evaluate the economic, regulatory, and health system factors driving drug development in cardiovascular disease.
In addition to the research, UCLH staff and LSE faculty and researchers will also jointly convene stakeholder events to increase impact and dissemination.